Physician profile
Michael Solomon
NPI 1205819026
$5,525.66
in general payments reported to CMS, 2019-2025
35 companies · $84.35 in 2025
The $84.35 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,050 · 2020: $1,171 · 2021: $422 · 2022: $626 · 2023: $644 · 2024: $527 · 2025: $84.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,255.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,204.37 | 2019-2024 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $1,086.69 | 2019-2024 | Fasenra, Andexxa, Breztri |
| Insmed, INC. | $831.82 | 2019-2024 | Arikayce |
| Boehringer Ingelheim Pharmaceuticals, INC. | $444.79 | 2019-2024 | Spiriva Respimat, Ofev |
| Actelion Pharmaceuticals US, INC. | $213.12 | 2019-2024 | Opsumit, Uptravi |
| Grifols USA, LLC | $196.08 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $139.36 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $131.08 | 2019-2023 | Dupixent |
| Genzyme Corporation | $118.79 | 2019-2021 | |
| United Therapeutics Corporation | $110.45 | 2019 | |
| Merck Sharp & Dohme LLC | $99.91 | 2019-2025 | Zerbaxa, Dificid, Bridion |
| Advanced Respiratory, INC | $87.89 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $79.18 | 2019-2023 | Xarelto |
| Mylan Specialty L.P. | $75.31 | 2020-2023 | Yupelri |
| Electromed, INC. | $66.04 | 2019-2024 | Smartvest |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $65.89 | 2019-2020 | |
| Boston Scientific Corporation | $61.47 | 2024-2025 | Varithena Administration Pack |
| Vapotherm INC | $48.47 | 2021-2022 | |
| Genentech USA, INC. | $48.24 | 2019 | |
| Gilead Sciences, INC. | $44.23 | 2019 | |
| Pfizer INC. | $41.56 | 2024 | |
| Mallinckrodt Hospital Products INC. | $36.03 | 2023 | Acthar |
| Laborie Medical Technologies Corp. | $32.86 | 2025 | Esense 7fr Abdominal Catheter |
| Circassia INC. | $29.76 | 2019-2020 | |
| Monaghan Medical Corporation | $28.90 | 2024 | Aerobika |
| Shire North American Group INC | $26.65 | 2019 | |
| Amgen INC. | $26.32 | 2022 | |
| Novartis Pharmaceuticals Corporation | $24.28 | 2021 | |
| Mallinckrodt Enterprises LLC | $23.77 | 2019 | |
| Daiichi Sankyo INC. | $22.06 | 2020 | |
| Alexion Pharmaceuticals, INC. | $19.76 | 2023 | Ultomiris |
| Resmed Corp | $18.82 | 2019 | |
| Baxter Healthcare | $17.62 | 2022 | |
| Pulmonx Corporation | $12.28 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.81 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Solomon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.